Leveraging oncovirus-derived antigen against the viral malignancies in adoptive cell therapies DOI Creative Commons
Wei Zhang, Miao Zeng, Yisheng Li

et al.

Biomarker Research, Journal Year: 2024, Volume and Issue: 12(1)

Published: July 29, 2024

Adoptive cell therapies (ACTs) have revolutionized cancer immunotherapy, prompting exploration into their application against oncoviruses. Oncoviruses such as human papillomavirus (HPV), hepatitis B virus (HBV), C (HCV), and Epstein-Barr (EBV) contribute significantly (12-25%) to malignancies through direct or indirect oncogenic mechanisms. These viruses persistently latently infect cells, disrupt cellular homeostasis pathways, challenging current antiviral treatment paradigms. Moreover, viral infections pose additional risks in the setting of long-term therapy lead morbidity mortality. Virally encoded oncoproteins, which are tumor-restricted, immunologically foreign, even uniformly expressed, represent promising targets for patient-tailored ACTs. This review elucidates rationale leveraging antigen-specific ACTs combating viral-associated malignancies. On this basis, ongoing preclinical studies consolidate our understanding harnessing malignancies, underscoring potential eradicate implicated progression. Furthermore, we scrutinize landscape clinical trials focusing on virus-specific discuss implications therapeutic advancement.

Language: Английский

Clinical Outcomes for Nasopharyngeal Cancer in Non-Asian Patients: A Single-Center Experience DOI Open Access
Renata Zahu,

Daniela Urian,

Vlad Manolescu

et al.

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(4), P. 1177 - 1177

Published: Feb. 11, 2025

Background/Objectives: According to Globocan, Romania has the highest incidence of nasopharyngeal cancer (NPC) in Europe. Our objective was evaluate survival data for a cohort non-Asian patient population treated with curative intent at tertiary center Romania. Methods: We retrospectively analyzed 161 patients histologically proven, non-metastatic NPC our institution between October 2014 and December 2021 intensity modulated arc radiotherapy (IMRT) or without neoadjuvant concomitant chemotherapy according stage disease. Kaplan-Meier estimates overall, disease-free, locoregional relapse free distant metastasis were calculated. The log-rank test used determine significant prognostic determinants overall disease-free survival. Results: median age 50 years (range 19–80), 88% had nonkeratinizing undifferentiated carcinoma. Epstein Barr virus status not evaluated routinely. 42.2% III 46% IVA Induction prescribed 72.7% 89.4% received concurrent chemotherapy. After follow up 44 months (range: 3.6, 104.7 months), estimated 3 disease free, entire 82.6%, 73.3%, 83.2% 86.3% respectively. On testing interactions, offered benefit (HR—0.287; 95% CI 0.137–0.603; p = 0.001) cumulative Cisplatin dose more than 100 mg/mp statistically (HR—0.350;95% 0.157–0.779; 0.01) Conclusions: This is largest retrospective series from reporting data. Despite high percentage advanced shows very good control. Compliance optimal should represent priority clinical practice population.

Language: Английский

Citations

0
Updates on Treatments and Management of Nasopharyngeal Carcinoma DOI
Melvin L.K. Chua, Xin Zhang, Kenneth C.W. Wong

et al.

American Society of Clinical Oncology Educational Book, Journal Year: 2025, Volume and Issue: 45(3)

Published: April 10, 2025

Nasopharyngeal carcinoma (NPC) is a unique head and neck cancer, where the endemic subtype strongly associated with Epstein-Barr virus (EBV) infection, whereas emerging data suggest that subset of nonendemic NPC may be human papillomavirus (HPV) infection. Nonetheless, treatment advances have been driven by clinical trials conducted in NPC, investigating optimal sequencing chemotherapy immune checkpoint inhibitors radiotherapy for locoregionally advanced disease. The preference induction (IC) these patients has also led to evolution concept target delineation. Because its association EBV, plasma EBV DNA an archetypal biomarker it being explored precise stratification individualization several ongoing trials. In space recurrent or metastatic-NPC, advent platinum-doublet anti–PD-1 antibody as new standard care, are immunotherapeutic combinations, bispecific antibodies, antibody-drug conjugates demonstrated promise early phase An important advance 2025 update 9th version TNM staging system, which introduced key changes, including downgrading stage groupings localized disease, splitting metastatic into IVA IVB based on number lesions. These revisions would implications design future relevant evidence inconclusive whether this disease responds differently current treatments compared NPC.

Language: Английский

Citations

0
Comparative evaluation of machine learning models in predicting overall survival for nasopharyngeal carcinoma using 18F-FDG PET-CT parameters DOI

Lin Duanyu,

Wenxi Wu,

Zongwei Huang

et al.

Clinical & Translational Oncology, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 20, 2024

Language: Английский

Citations

1
Leveraging oncovirus-derived antigen against the viral malignancies in adoptive cell therapies DOI Creative Commons
Wei Zhang, Miao Zeng, Yisheng Li

et al.

Biomarker Research, Journal Year: 2024, Volume and Issue: 12(1)

Published: July 29, 2024

Adoptive cell therapies (ACTs) have revolutionized cancer immunotherapy, prompting exploration into their application against oncoviruses. Oncoviruses such as human papillomavirus (HPV), hepatitis B virus (HBV), C (HCV), and Epstein-Barr (EBV) contribute significantly (12-25%) to malignancies through direct or indirect oncogenic mechanisms. These viruses persistently latently infect cells, disrupt cellular homeostasis pathways, challenging current antiviral treatment paradigms. Moreover, viral infections pose additional risks in the setting of long-term therapy lead morbidity mortality. Virally encoded oncoproteins, which are tumor-restricted, immunologically foreign, even uniformly expressed, represent promising targets for patient-tailored ACTs. This review elucidates rationale leveraging antigen-specific ACTs combating viral-associated malignancies. On this basis, ongoing preclinical studies consolidate our understanding harnessing malignancies, underscoring potential eradicate implicated progression. Furthermore, we scrutinize landscape clinical trials focusing on virus-specific discuss implications therapeutic advancement.

Language: Английский

Citations

0